Trojan Horse-like Therapy a New Tool in Cancer Treatment Arsenal

More exciting news in cancer treatment!

One of the perplexing things about cancer treatment (chemotherapeutics) is that the substances used to kill the tumors are poisonous… even deadly toxic. It has been, in essence, a shotgun approach. That is, while the malignant cells targeted for destruction are killed, so are other, non-cancerous cells throughout the body. It is an imprecise treatment because the intravenous treatment circulates throughout the entire body.

This new approach is – as the story describes – somewhat like the proverbial Trojan Horse.

—

A New Class of Cancer Drugs May Be Less Toxic

May 31, 2012
By ANDREW POLLACK

Fern Saitowitz’s advanced breast cancer was controlled for about a year by the drug Herceptin and a toxic chemotherapy agent. But her hair fell out, her fingernails turned black and she was constantly fatigued.

She switched to an experimental treatment, which also consisted of Herceptin and a chemotherapy agent. Only this time, the two drugs were attached to each other, keeping the toxic agent inactive until the Herceptin carried it to the tumor. Side effects, other than temporary nausea and some muscle cramps, vanished.

“I’m able to live a normal life,” said Ms. Saitowitz, 47, a mother of two young children in Los Angeles. “I haven’t lost any of my hair.”

The experimental treatment, called T-DM1, is a harbinger of a new class of cancer drugs that may be more effective and less toxic than many existing treatments. By harnessing antibodies to deliver toxic payloads to cancer cells, while largely sparing healthy cells, the drugs are a step toward the “magic bullets” against cancer first envisioned by Paul Ehrlich, a German Nobel laureate, about 100 years ago.

“It’s almost like we’re

New Hope in Cancer Treatment May Soon Be Widely Available

In a nutshell, cancer is simply a case of good and normal cells which have “gone bad,” which are typically characterized by rapid reproduction of those mutated cells, accompanied by the development of its own network of blood vessels to feed its growth (angiogenesis).

The initial findings in this research are indeed promising.

—

Drug Helps Defense System Fight Cancer

June 1, 2012 By ANDREW POLLACK

CHICAGO — One of the great frustrations for researchers in the war on cancer is that the body’s own defense system does not do a better job fighting the disease. Tumors, it turns out, have a molecular shield that repels attacks from the immune system.

Now, a new study says, an experimental drug is showing promise in disabling that shield, unleashing the immune system and causing shrinkage of some lung, skin and kidney cancers that had defied treatment with existing drugs.

“We are seeing responses in heavily treated patients — three different cancers, one drug,” Dr. Suzanne L. Topalian, a melanoma specialist at Johns Hopkins University and lead investigator in the study, said in an interview. “This is a group of patients whose life expectancy was measured in a few months.”

The results are from